Alnylam Pharmaceuticals, Inc.
Alnylam is leading the translation of RNAi into a new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases.
The acute hepatic porphyrias are ultra-rare, often misdiagnosed genetic diseases characterized by acute attacks and debilitating multi-system symptoms.